Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,998 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Doshi AS, Cantin S, Hernandez M, Srinivasan S, Tentarelli S, Griffin M, Wang Y, Pop-Damkov P, Prickett LB, Kankkonen C, Shen M, Martin MS, Wu S, Castaldi MP, Ghadially H, Varnes J, Gales S, Henry D, Hoover C, Mele DA, Simpson I, Gangl ET, Mlynarski SN, Finlay MRV, Drew L, Fawell SE, Shao W, Schuller AG. Doshi AS, et al. Among authors: griffin m. Mol Cancer Ther. 2023 May 4;22(5):630-645. doi: 10.1158/1535-7163.MCT-22-0431. Mol Cancer Ther. 2023. PMID: 36912782
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P. Proia TA, et al. Among authors: griffin m. Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943458
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, Meekin J 3rd, Griffin M, Bisha I, Proia TA, Miragaia RJ, Herbst R, Gupta A, Abdullah SE, Raja R, Frigault MM, Barrett JC, Dennis PA, Ascierto ML, Oberst MD. Pore N, et al. Among authors: griffin m. Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6. Cancer Discov. 2021. PMID: 34230008
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
Vasalou C, Proia TA, Kazlauskas L, Przybyla A, Sung M, Mamidi S, Maratea K, Griffin M, Sargeant R, Urosevic J, Rosenbaum AI, Yuan J, Aluri KC, Ramsden D, Hariparsad N, Jones RDO, Mettetal JT. Vasalou C, et al. Among authors: griffin m. CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):994-1005. doi: 10.1002/psp4.13133. Epub 2024 Mar 26. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38532525 Free PMC article.
Enhancing lung transplantation with ECMO: a comprehensive review of mechanisms, outcomes, and future considerations.
Pervaiz Butt S, Kakar V, Abdulaziz S, Razzaq N, Saleem Y, Kumar A, Ashiq F, Ghisulal P, Thrush A, Malik S, Griffin M, Amir M, Khan U, Salim A, Zoumot Z, Mydin I, Aljabery Y, Bhatnagar G, Bayrak Y, Obeso A, Ahmed U. Pervaiz Butt S, et al. Among authors: griffin m. J Extra Corpor Technol. 2024 Dec;56(4):191-202. doi: 10.1051/ject/2024023. Epub 2024 Dec 20. J Extra Corpor Technol. 2024. PMID: 39705583 Free PMC article. Review.
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH.
Kulasekararaj AG, Griffin M, Piatek CI, Shammo J, Nishimura JI, Patriquin CJ, Schrezenmeier H, Barcellini W, Panse JP, Gaya A, Patel Y, Liu P, Filippov G, Sicre de Fontbrune F, Risitano AM, Lee JW. Kulasekararaj AG, et al. Among authors: griffin m. Blood. 2024 Dec 19:blood.2024026299. doi: 10.1182/blood.2024026299. Online ahead of print. Blood. 2024. PMID: 39700502
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
da Fonseca ARB, Justino CC, de Molla VC, Yamakawa PE, Rabelo IB, Arnold LM, Kelly RJ, Griffin M, Munir T, Hill A, Velloso EDRP, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj AG, Arrais-Rodrigues C. da Fonseca ARB, et al. Among authors: griffin m. Blood Adv. 2024 Dec 18:bloodadvances.2024014159. doi: 10.1182/bloodadvances.2024014159. Online ahead of print. Blood Adv. 2024. PMID: 39693508
2,998 results